Provectus Biopharmaceuticals Financials
| PVCTDelisted Stock | USD 0.11 0.00 0.00% |
With this module, you can analyze Provectus financials for your investing period. You should be able to track the changes in Provectus Biopharmaceutica individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Provectus |
Understanding current and past Provectus Biopharmaceutica Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Provectus Biopharmaceutica's financial statements are interrelated, with each one affecting the others. For example, an increase in Provectus Biopharmaceutica's assets may result in an increase in income on the income statement.
The data published in Provectus Biopharmaceutica's official financial statements usually reflect Provectus Biopharmaceutica's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Provectus Biopharmaceutica. For example, before you start analyzing numbers published by Provectus accountants, it's critical to develop an understanding of what Provectus Biopharmaceutica's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Provectus Biopharmaceutica's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Provectus Biopharmaceutica's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Provectus Biopharmaceutica's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Provectus Biopharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Provectus Biopharmaceutica's management manipulating its earnings.
Provectus Biopharmaceutica Stock Summary
Provectus Biopharmaceutica competes with Aerovate Therapeutics, Celldex Therapeutics, Kiniksa Pharmaceuticals, Cerevel Therapeutics, and Crinetics Pharmaceuticals. Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee. Provectus Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.Specialization | Healthcare, Biotechnology |
| Instrument | USA OTC Stock View All |
| Exchange | OTCQB Exchange |
| ISIN | US74373P1084 |
| CUSIP | 74373P108 74373F100 |
| Location | Tennessee; U.S.A |
| Business Address | 10025 Investment Drive, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.provectusbio.com |
| Phone | 866 594 5999 |
| Currency | USD - US Dollar |
You should never invest in Provectus Biopharmaceutica without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Provectus OTC Stock, because this is throwing your money away. Analyzing the key information contained in Provectus Biopharmaceutica's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Provectus Biopharmaceutica Key Financial Ratios
Generally speaking, Provectus Biopharmaceutica's financial ratios allow both analysts and investors to convert raw data from Provectus Biopharmaceutica's financial statements into concise, actionable information that can be used to evaluate the performance of Provectus Biopharmaceutica over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Provectus Biopharmaceutica reports annually and quarterly.Provectus Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Provectus Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Provectus Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Provectus Biopharmaceutica competition to find correlations between indicators driving Provectus Biopharmaceutica's intrinsic value. More Info.Provectus Biopharmaceuticals is rated below average in return on asset category among related companies. It is regarded second in operating margin category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Provectus Biopharmaceutica by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Provectus Biopharmaceutica's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Provectus Biopharmaceutica's earnings, one of the primary drivers of an investment's value.Provectus Biopharmaceutica Market Pulse
| Quote | 0.11 |
| Change(%) | 0.00 |
| Change | 0.00 |
| Open | 0.11 |
| Low | 0.11 |
| High | 0.11 |
| Volume | 0 |
| Exchange | OTCQB |
About Provectus Biopharmaceutica Financials
What exactly are Provectus Biopharmaceutica Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Provectus Biopharmaceutica's income statement, its balance sheet, and the statement of cash flows. Potential Provectus Biopharmaceutica investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Provectus Biopharmaceutica investors may use each financial statement separately, they are all related. The changes in Provectus Biopharmaceutica's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Provectus Biopharmaceutica's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Provectus Biopharmaceutica Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Provectus Biopharmaceutica is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Provectus has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Provectus Biopharmaceutica's financials are consistent with your investment objective using the following steps:- Review Provectus Biopharmaceutica's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Provectus Biopharmaceutica's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Provectus Biopharmaceutica's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Provectus Biopharmaceutica's stock is overvalued or undervalued.
Provectus Biopharmaceutica April 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Provectus Biopharmaceutica help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Provectus Biopharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Provectus Biopharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Provectus OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Provectus Biopharmaceutica's daily price indicators and compare them against related drivers.
| Downside Deviation | 9.26 | |||
| Information Ratio | 0.0779 | |||
| Maximum Drawdown | 58.93 | |||
| Value At Risk | (12.50) | |||
| Potential Upside | 15.38 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |